ArticleClinical oral investigations2026
Multifunctional dual drug-loaded Gel-Alg/MINO/MEL composite hydrogel for combating three-dimensional multi-species biofilm and experimental periodontitis treatment.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesAdjunctive drug therapy is indispensable in periodontitis treatment. Currently, such pharmacotherapy is not ideal, so new formulations need to be explored to optimize prolonged in situ slow release of active ingredients, biocompatibility, and preparation costs. This study constructed an injectable dual drug delivery composite hydrogel system (Gel-Alg/MINO/MEL) to locally deliver minocycline hydrochloride (MINO) and melatonin (MEL) for antibacterial, anti-inflammatory, antioxidant effects and bone formation. MATERIALS AND
methodsWe tested the release kinetics of Gel-Alg/MINO/MEL, evaluated its in vitro and in vivo biocompatibility, and detected its in vitro effects on multi-species biofilm, pro-inflammatory cytokines, related genes/proteins and reactive oxygen species, as well as in vivo effects on periodontal inflammation and tissue reconstruction.
resultsRelease kinetics showed Gel-Alg/MINO/MEL continuously released MINO and MEL for over 10 days with good biocompatibility. In vitro, it inhibited biofilm formation, reduced pro-inflammatory cytokines, increased related genes/proteins expression and scavenged excessive reactive oxygen species; in vivo, it relieved periodontal inflammation and promoted tissue reconstruction and collagen fiber attachment.
conclusionsThe Gel-Alg/MINO/MEL hydrogel has promising potential as a local drug delivery system for treating periodontitis, with favorable sustained release and biocompatibility. CLINICAL RELEVANCE: Regular placement of the Gel-Alg/MINO/MEL composite hydrogel in periodontal pockets, in conjunction with basic clinical periodontal treatment, might remodel the bone and soft tissues lost during periodontitis. Therefore, this is expected to be a more effective medication-assisted treatment modality for refractory periodontitis.
Indexed as
Identifiers
42560526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.